Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024
Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company focused on orthopedic surgery, will participate in the LD Micro Main Event XVII Conference on October 29-30, 2024 in Los Angeles. CFO Noel Knape will conduct one-on-one meetings and deliver a presentation on October 30 at 12:30 pm PT.
The company will showcase its mBôs precision robotic surgical system, designed to autonomously execute optimized paths for high-precision insertion of FDA-cleared mPress press-fit implants for total knee replacements. The presentation will be available via webcast and on Monogram's investor relations website.
Investors can schedule meetings with management by contacting their conference representative or emailing MGRM@mzgroup.us.
Monogram Technologies (NASDAQ:MGRM), un'azienda di robotica guidata dall'IA focalizzata sulla chirurgia ortopedica, parteciperà alla LD Micro Main Event XVII Conference il 29-30 Ottobre 2024 a Los Angeles. Il CFO Noel Knape condurrà incontri individuali e presenterà una relazione il 30 Ottobre alle 12:30 ora del Pacifico.
L'azienda presenterà il suo sistema chirurgico robotico di precisione mBôs, progettato per eseguire autonomamente percorsi ottimizzati per l'inserimento di impianti mPress approvati dalla FDA per le sostituzioni totali del ginocchio. La presentazione sarà disponibile tramite webcast e sul sito delle relazioni con gli investitori di Monogram.
Gli investitori possono programmare incontri con la direzione contattando il loro rappresentante della conferenza o inviando un'email a MGRM@mzgroup.us.
Monogram Technologies (NASDAQ:MGRM), una empresa de robótica impulsada por IA centrada en la cirugía ortopédica, participará en la LD Micro Main Event XVII Conference el 29-30 de octubre de 2024 en Los Ángeles. El CFO Noel Knape realizará reuniones uno a uno y dará una presentación el 30 de octubre a las 12:30 p.m. PT.
La empresa mostrará su sistema quirúrgico robótico de precisión mBôs, diseñado para ejecutar de manera autónoma caminos optimizados para la inserción de implantes mPress aprobados por la FDA para reemplazos totales de rodilla. La presentación estará disponible a través de un webcast y en el sitio web de relaciones con inversionistas de Monogram.
Los inversores pueden programar reuniones con la dirección contactando a su representante de la conferencia o enviando un correo electrónico a MGRM@mzgroup.us.
모노그램 기술 (NASDAQ:MGRM), 정형외과 수술에 중점을 둔 AI 기반 로봇 회사가 LD 마이크로 메인 이벤트 XVII 컨퍼런스에 참석할 예정입니다. 날짜는 2024년 10월 29-30일로 로스앤젤레스에서 열립니다. CFO 노엘 크나페가 일대일 회의를 진행하고 10월 30일 오후 12시 30분(태평양 표준시)에 발표를 할 예정입니다.
회사는 FDA 승인된 mPress 프레스핏 임플란트를 위한 정밀한 로봇 외과 시스템인 mBôs를 선보일 것입니다. 이 발표는 웹캐스트를 통해 제공되며 모노그램의 투자자 관계 웹사이트에서도 볼 수 있습니다.
투자자들은 컨퍼런스 대표에게 연락하거나 MGRM@mzgroup.us로 이메일을 보내어 경영진과의 회의를 예약할 수 있습니다.
Monogram Technologies (NASDAQ:MGRM), une entreprise de robotique axée sur l'IA spécialisée dans la chirurgie orthopédique, participera à la LD Micro Main Event XVII Conference les 29-30 octobre 2024 à Los Angeles. Le CFO Noel Knape mènera des réunions individuelles et fera une présentation le 30 octobre à 12h30 PT.
L'entreprise présentera son système chirurgical robotique de précision mBôs, conçu pour exécuter de manière autonome des chemins optimisés pour l'insertion précise d'implants mPress approuvés par la FDA pour les remplacements complets du genou. La présentation sera disponible via un webcast et sur le site des relations investisseurs de Monogram.
Les investisseurs peuvent planifier des réunions avec la direction en contactant leur représentant de la conférence ou en envoyant un courriel à MGRM@mzgroup.us.
Monogram Technologies (NASDAQ:MGRM), ein KI-gesteuertes Robotikunternehmen mit Fokus auf orthopädische Chirurgie, wird an der LD Micro Main Event XVII Conference am 29.-30. Oktober 2024 in Los Angeles teilnehmen. CFO Noel Knape wird Einzelgespräche führen und am 30. Oktober um 12:30 Uhr PT eine Präsentation halten.
Das Unternehmen wird sein mBôs präzises robotisches chirurgisches System vorstellen, das darauf ausgelegt ist, autonom optimierte Wege für die hochpräzise Einsetzung von FDA-zugelassenen mPress Press-Fit-Implantaten für totale Kniegelenkersatzoperationen auszuführen. Die Präsentation wird über einen Webcast und auf der Investor Relations-Website von Monogram verfügbar sein.
Investoren können Meetings mit dem Management planen, indem sie ihren Konferenzvertreter kontaktieren oder eine E-Mail an MGRM@mzgroup.us senden.
- None.
- None.
AUSTIN, TX / ACCESSWIRE / October 16, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will attend the LD Micro Main Event XVII Conference being held at the Luxe Sunset Blvd Hotel in Los Angeles, CA October 29 - 30, 2024.
Monogram Chief Financial Officer Noel Knape will conduct in-person one-on-one meetings during the conference to discuss the Company's novel mBôs precision robotic surgical system. Monogram's mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants with the goal of achieving better total knee replacement patient outcomes. Mr. Knape will also host a presentation which can be viewed live and via replay at the webcast registration link below and will also be available on the Monogram investor relations website at ir.monogramorthopedics.com.
LD Micro Main Event XVII
Date: October 29 - 30, 2024
Location: Luxe Sunset Blvd Hotel, Los Angeles, CA
Presentation Time: Wednesday October 30, 2024, at 12:30 pm PT/3:30 pm ET in Track 2
Webcast Registration: https://me24.sequireevents.com/
Speaker: CFO Noel Knape
Format: In-person 1x1's and Presentations
Conference Website: Click here
For more information on the LD Micro Main Event XVII Conference or to schedule a one-on-one meeting with Monogram Technologies management, please contact your conference representative or you may also email your request to MGRM@mzgroup.us or call Chris Tyson at (949) 491-8235.
For more information about Monogram Technologies, please visit ir.monogramorthopedics.com.
About Monogram Technologies Inc.
Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.
Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.
Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.
The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.
To learn more, visit monogramtechnologies.com.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. For example, the Company's statement regarding the Company's proposed use of net proceeds is a forward-looking statement. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
MGRM@mzgroup.us
SOURCE: Monogram Technologies Inc.
View the original press release on accesswire.com
FAQ
When and where is Monogram Technologies (MGRM) presenting at the LD Micro Main Event XVII Conference?
What will Monogram Technologies (MGRM) discuss at the LD Micro Main Event XVII Conference?
How can investors schedule a meeting with Monogram Technologies (MGRM) management at the conference?
Where can investors view Monogram Technologies' (MGRM) presentation from the LD Micro Main Event XVII Conference?
